The characteristics of the technological paradigm of targeted therapies for lung cancer are that inhibits the tyrosine kinase activity of EGFR, which is overproduced by lung cancer. Some properties of this technological paradigm are: Therapeutic ones: antineoplastic activity; the inhibition of signal transduction (blocking the signal transduction events and tumorigenic effects associated with epidermal growth factor receptor -EGFR- activation); induce cell cycle arrest and inhibit angiogenesis. Innovative ones: - "learning via diffusion" (Sahal, 1981, p. 114): the increased adoption of this technological approach paves the way for improvement in its characteristics. bidirectional learning process based on an intensive intertwined relationship that runs from breakthroughs in basic biomedical sciences, clinical research to clinical practice, and vice versa. This learning process has causal arrows going both ways, between basic research of scientists and clinical research with the participation of patients and medical staff; - the highest scientific and technological rate of knowledge growth in comparison with traditional chemotherapy agents.
Structure of technological paradigm of the target therapies for lung cancer: Theoretical framework for anticancer groundbreaking anticancer drugs
Coccia M
2012
Abstract
The characteristics of the technological paradigm of targeted therapies for lung cancer are that inhibits the tyrosine kinase activity of EGFR, which is overproduced by lung cancer. Some properties of this technological paradigm are: Therapeutic ones: antineoplastic activity; the inhibition of signal transduction (blocking the signal transduction events and tumorigenic effects associated with epidermal growth factor receptor -EGFR- activation); induce cell cycle arrest and inhibit angiogenesis. Innovative ones: - "learning via diffusion" (Sahal, 1981, p. 114): the increased adoption of this technological approach paves the way for improvement in its characteristics. bidirectional learning process based on an intensive intertwined relationship that runs from breakthroughs in basic biomedical sciences, clinical research to clinical practice, and vice versa. This learning process has causal arrows going both ways, between basic research of scientists and clinical research with the participation of patients and medical staff; - the highest scientific and technological rate of knowledge growth in comparison with traditional chemotherapy agents.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
